Tillotts Pharma AG (CH)

https://www.tillotts.com

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with close to 400 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialization of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world. *

	Start	2009-09-01 existent
	Group	Zeria (Group)
	Industry	gastrointestinal drug
	Industry 2	Asacol® (mesalamine)
	Person	Tóth von Kiskér, Thomas A. (Zeria 202005 CEO of Tillotts Pharma AG)
	Person 2	Spleiss, Johannes (Zeria 202307 Head Scientific Affairs Tillotts Pharma + 202307– CEO of Mage Biologics)

	Street	15 Baslerstr.
	City	4310 Rheinfelden
	Tel	+41-61-935-2626
		Address record changed: 2023-07-30

Basic data	Employees	D: 101 to 500 (2014-11-16)

		* Document for »About Section«: Tillotts Pharma AG. (7/20/23). "Press Release: Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis". Montréal, Munich & Rheinfelden.

		Record changed: 2023-07-31

Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x200px

More documents for Zeria (Group)

[1] Tillotts Pharma AG. (7/20/23). "Press Release: Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis". Montréal, Munich & Rheinfelden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]